Stalicla

STALICLA at MedInvest – Neurological Diseases & Mental Health Disorders Conference

Geneva, Switzerland, September 8, 2021 — STALICLA, a Swiss clinical-stage biotech company advancing precision medicine to patients with Autism Spectrum Disorders and other Neurodevelopmental Disorders, announced today that its CEO and Founder, Lynn Durham, will present at the THE NEUROLOGICAL DISEASES & MENTAL HEALTH DISORDERS CONFERENCE, on September 9, 2021. Ms Durham’s presentation will take …

STALICLA at MedInvest – Neurological Diseases & Mental Health Disorders Conference Read More »

STALICLA at MedInvest – Neurological Diseases & Mental Health Disorders Conference

STALICLA at Swiss Biotech Day 2021

Tuesday, July 6, 2021 STALICLA at the Venture Summit Virtual Connect Event, from the 6th – 8th of July

STALICLA is delighted to be attending the BioTrinity 2021 Digital Event, from the 21st – 22nd of June

STALICLA is delighted to be attending the 21st BIO Digital Europe Global Digital Event – 10th to 18th of June

STALICLA Appoints Baltazar Gomez-Mancilla, MD, PhD, as Chief Medical Officer

STALICLA selected to give two scientific oral presentations at the International Society for Autism Research (INSAR) 2021 Annual Meeting! (held virtually)

Our Founder & CEO, Lynn Durham, will be presenting STALICLA on April 30th, 2021 on the Digital Platforms & Therapeutics: Advancing the Frontiers of Care Panel at SACHS 4th Annual Neuroscience Innovation Forum.

STALICLA’s CEO, Lynn-Allison Durham and Head of Discovery, Laura Perez Cano, will present at the 11th Clinical Biomarkers & World CDx EU Summit this Wednesday, March 24th.

STALICLA will meet investors at the BIO-Europe Spring Digital event on March 22nd-25th.